• national-geographic-logo.jpg

    National Geographic recommends which vaccines you can trust

    22 Sep, 2020

    More than 150 coronavirus vaccines are in development across the world—and hopes are high to bring one to market in record time to ease the global crisis. Several efforts are underway to help make that possible, including the U.S. government’s Operation Warp Speed initiative, which has pledged $10 billion and aims to develop and deliver 300 million doses of a safe, effective coronavirus vaccine by January 2021. The World Health Organization is also coordinating global efforts to...
  • Captura_de_pantalla_2020-09-18_a_las_12_18_47.png

    Preprints with The Lancet are here to stay

    18 Sep, 2020
    The Lancet confirms that preprint paper will stay in their future strategy. 



    For full reading download the document.

  • vaccine-covid-19-brazil.jpg

    Elimination of COVID-19: what would it look like and is it possible?

    30 Aug, 2020
    In countries that have achieved a low incidence of COVID-19 infection, such as Australia and New Zealand, disease elimination has been proposed. Yet we do not have a definition of elimination for COVID-19. Both these countries implemented early, widespread, and strict disease mitigation strategies. With low cumulative incidence, most of the population in these countries remain susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Before the availability of a vaccin...
  • FDA-logo.png

    Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing

    18 Aug, 2020

    Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection.

    “The SalivaDirect test for rapid detection of SARS-CoV-2 is yet another testing innovation game changer that will reduce the demand for scarce testing resources,” said Assistant Secretary for Health and COVID-19 Testing Coo...
  • 79454F5E-8A73-4F61-84F6-7642A95C1824.jpeg

    Coronavirus vaccine from Oxford and AstraZeneca shows positive response in early trial

    13 Aug, 2020

    A potential coronavirus vaccine developed by Oxford University with pharmaceutical giant AstraZeneca has produced a promising immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet.

    The researchers are calling their experimental vaccine ChAdOx1 nCoV-19 (AZD1222). It combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees...
  • chemo.jpg

    Chemotherapy in cancer patients with Covid-19 'not a risk'

    7 Aug, 2020

    Continuing chemotherapy and immunotherapy treatment in cancer patients with Covid-19 is not a risk to their survival, a study suggests.

    It also recommends further research into the drug hydroxychloroquine, which appeared to benefit some patients.

    The findings, from 890 infected cancer patients in the UK, Spain, Italy and Germany, could help identify who is most at risk from coronavirus.

    Breast cancer patients had half the death rate of other patients.

    The Imper...
  • vaccine2.jpg

    Coronavirus vaccine tracker: how close are we to a vaccine?

    30 Jul, 2020
    More than 140 teams of researchers are racing to develop a safe and effective coronavirus vaccine.

    Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO).

    Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within 12 to 18 months.

    Vaccines mimic the...
  • vacuna-covid19.jpg

    Coronavirus: Protein treatment trial 'a breakthrough'

    28 Jul, 2020

    The preliminary results of a clinical trial suggest a new treatment for Covid-19 reduces the number of patients needing intensive care, according to the UK company that developed it.

    The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection.

    The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune respon...
  • good_news.png

    Dexamethasone in Hospitalized Patients with Covid-19 | NEJM

    19 Jul, 2020


    An study of the RECOVERY Group bring good news about the use of Dexamethasone in COVID-19 patients. 

    Background

    Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

    Methods

    In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we ra...
  • vaccine4.jpg

    $2bn global coronavirus vaccine fund announced at Gavi summit

    5 Jun, 2020

    A $2bn procurement fund aimed at ensuring that poorer countries can access doses of a potential coronavirus vaccine has been announced at a virtual summit hosted by the UK.



    The announcement was made at the third Gavi vaccine alliance replenishment summit, a virtual pledging event that separately raised $8.8bn, above the target of $7.4bn, for the private-public alliance’s general work on immunising millions of people worldwide from longstanding diseases such as measles.
    <...
  • vaxin.jpg

    Fauci says he's optimistic about coronavirus vaccine protection, but concerned about how long that protection will last

    4 Jun, 2020

    The USA's leading infectious disease expert Dr. Anthony Fauci said he’s “cautiously optimistic” a coronavirus vaccine will provide some protection against SARS-CoV-2 and COVID-19, the illness it causes, but is concerned about how long that protection could last.

    In an interview with JAMA editor-in-chief Howard Bauchner Tuesday, the director of the National Institute of Allergy and Infectious Diseases questioned the "durability" of candidate vaccines.

    Click here for refe...
  • vaccine3.jpg

    In-home antibody test shows promise; recovering surgery patients at risk from coronavirus

    2 Jun, 2020
    The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

    In-home COVID-19 antibody test shows high accuracy

    Recovering surgery patients at risk from coronavirus

    Immune system overreaction may not be cause of bad outcomes

    COVID-19 survivors will need rehab therapy, experts say


    Click here for reference